Here's Why The Clouds Have Lifted For Quest Diagnostics
A quicker than expected recovery in routine testing and expansion in COVID-19 testing is driving better anticipated projected earnings for the second quarter.
Will Walgreens Investors Be Rewarded For Patience?
The eventual stabilization in the business, a high dividend yield, and strong financial resources more than offset the near-term impact of COVID-19 on this pharmacy business.
Here's Why Regeneron’s Stock Is Worth More Than Its Coronavirus Work
The company should benefit from continued growth in its core business of treating patients with eye disease, eczema, asthma, and cancer.
Here's Why Sanofi Is An Underappreciated Coronavirus Stock
The pharma company is making progress on its portfolio of coronavirus therapies and the execution of its new growth strategy.
For Gilead, Its Coronavirus Treatment Candidate Is Icing on the Cake
There are three good reasons to own Gilead aside from Remdesivir.
3 High-Yielding U.S. Pharmaceutical Companies to Consider
These businesses have the winning trifecta: a stable dividend, ongoing earnings growth, and attractive valuation.